FDA's Rx/Dx Draft Guidance Urges Simultaneous Development, but Addresses Alternative Scenarios | GenomeWeb

By Turna Ray

A long-awaited
draft guidance issued by the US Food and Drug Administration this week clarifies which in vitro diagnostics fall into the agency's definition of a companion test and outlines various drug/diagnostic codevelopment scenarios in which the agency would allow sponsors to market tests that don't have 510(k) clearance or premarket approval.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.